Developmental neuroscience

Three New Autism Centers for Children Opening This Week in Twin Cities Metro Area

Retrieved on: 
Thursday, June 25, 2020
Psychiatry, Psychiatric diagnosis, Autism, Abnormal psychology, Health, Learning disabilities, Autism spectrum, Developmental neuroscience, Developmental psychology

MINNEAPOLIS, June 25, 2020 /PRNewswire/ --Caravel Autism Health is hosting grand opening events at three new autism therapy centers in the Twin Cities metropolitan area this week.

Key Points: 
  • MINNEAPOLIS, June 25, 2020 /PRNewswire/ --Caravel Autism Health is hosting grand opening events at three new autism therapy centers in the Twin Cities metropolitan area this week.
  • Parents in the Twin Cities region can call 507-322-7752 to schedule appointments with Caravel's autism health specialists.
  • The three new centers are located at:
    Caravel Autism Health has already opened the doors to autism therapy centers in White Bear Lake, Woodbury, Mankato, and Rochester.
  • Caravel's team of autism health experts specializes in the evaluation, diagnosis and treatment of children on the autism spectrum.

Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare Conference

Retrieved on: 
Wednesday, May 27, 2020
Mental health, Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Organ systems, Nervous system, Medical specialties, Developmental neuroscience, Neurodevelopmental disorder, Parkinson's disease

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET.

Key Points: 
  • Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET.
  • Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases.
  • The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinsons Disease and Autism Spectrum Disorder.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005109/en/

Cabaletta Bio Announces Presentation of Data Supporting MuSK-CAART Development for the Treatment of the MuSK form of Myasthenia Gravis at the AAN 2020 Science Highlights Virtual Platform

Retrieved on: 
Monday, May 18, 2020
Branches of biology, Immunology, Biology, Developmental neuroscience, Proteins, MuSK protein, Antibody, Immunosuppressive drug

Cabaletta Bio has exclusively licensed the MuSK CAAR T cell technology from and has developed the therapy in partnership with the University of Pennsylvania.

Key Points: 
  • Cabaletta Bio has exclusively licensed the MuSK CAAR T cell technology from and has developed the therapy in partnership with the University of Pennsylvania.
  • Patients who suffer from MuSK MG have very limited therapeutic options, primarily generalized immunosuppressants, which typically require chronic administration, and can cause significant side effects.
  • In addition, MuSK CAAR T cells also targeted and eliminated a panel of B cells targeting different MuSK epitopes.
  • This study demonstrated that MuSK CAAR T cells were able to deplete B cells expressing anti-MuSK antibodies.

CentralReach Helps Keep Autism Therapy Clinicians Certified to Provide Care in Wake of COVID-19

Retrieved on: 
Friday, April 10, 2020
Psychology, Human behavior, Psychiatry, Psychiatric diagnosis, Learning disabilities, Autism, Pervasive developmental disorders, Autism spectrum, Developmental neuroscience, Applied behavior analysis

With only an estimated 38,000 BCBAs to provide care for millions of people with autism spectrum disorder, the industry already faced a capacity constraint and any additional loss of BCBAs in market due to COVID-19 would be devastating to those seeking care.

Key Points: 
  • With only an estimated 38,000 BCBAs to provide care for millions of people with autism spectrum disorder, the industry already faced a capacity constraint and any additional loss of BCBAs in market due to COVID-19 would be devastating to those seeking care.
  • These clinicians have enough on their plates as it is and worrying about if theyre going to lose their certification shouldnt be one of them.
  • CentralReach has also created a business and care continuity resources page so ABA clinicians and educators can access resources and information designed to help them navigate through the Coronavirus pandemic.
  • CentralReach is a leading provider of end-to-end practice management and clinical solutions that enable applied behavior analysis (ABA) clinicians and educators to produce superior outcomes for people with autism.

Meritech Selects DevelopmentalFX as Philanthropic Partner to Support Children with Neurodevelopmental Disorders

Retrieved on: 
Monday, March 9, 2020
Psychiatry, Developmental neuroscience, Psychiatric diagnosis, Neuroscience, Organ systems, Developmental disabilities, Childhood psychiatric disorders, Neurodevelopmental disorders, Developmental disorder, Mental disorder

"DevelopmentalFX stood out to us among the charitable organizations we considered due to their truly unique approach in empowering children, families, schools, and communities that are affected by neurodevelopmental disorders so that all children may be uplifted to achieve their fullest potential."

Key Points: 
  • "DevelopmentalFX stood out to us among the charitable organizations we considered due to their truly unique approach in empowering children, families, schools, and communities that are affected by neurodevelopmental disorders so that all children may be uplifted to achieve their fullest potential."
  • DevelopmentalFX is a nonprofit organization based in Denver, Colorado that works with children that have a range of learning and developmental disabilities.
  • "We are thrilled to partner with Meritech in supporting their organizational mission and values while also galvanizing community support to transform the lives of children and families affected by neurodevelopmental disorders," says Tracy Stackhouse, DevelopmentalFX Co-Founder, and Executive Director.
  • DevelopmentalFX is a Denver-based nonprofit organization whose mission is to transform the lives of children and families affected by neurodevelopmental disorders so that they can live to their fullest potential.

Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population

Retrieved on: 
Tuesday, March 3, 2020
Psychiatry, Abnormal psychology, Autism, Psychiatric diagnosis, Pervasive developmental disorders, Health, Communication disorders, Developmental neuroscience, Autism spectrum, Autism Diagnostic Observation Schedule, Developmental disorder, Spectrum disorder

These data will also be presented during the ASENT Pipeline Data Blitz session on Wednesday March 4, 2020 from 1:00 to 3:00PM EST.

Key Points: 
  • These data will also be presented during the ASENT Pipeline Data Blitz session on Wednesday March 4, 2020 from 1:00 to 3:00PM EST.
  • The meeting is being held in Bethesda, MD on March 2nd through March 5th, 2020.
  • These include the Aberrant Behavior Checklist Community (ABC-C); the Autism Diagnostic Observation Schedule (ADOS-2); and the Parent Rated Anxiety ScaleAutism Spectrum Disorder (PRAS-ASD).
  • ASD is a complex neurodevelopmental disorder characterized by difficulties with behaviors, communication, and social interaction,said Dr. Palumbo.

Hopebridge Brings Pediatric Autism Therapy Centers into Colorado

Retrieved on: 
Wednesday, February 26, 2020
Psychology, Psychiatry, Psychiatric diagnosis, Human behavior, Pervasive developmental disorders, Learning disabilities, Developmental neuroscience, Autism, Applied behavior analysis, Outline of autism, Autism therapies

Hopebridges mission is to help as many children with autism spectrum disorder as possible, said Hopebridge Vice President of Business Development Chris Sutton.

Key Points: 
  • Hopebridges mission is to help as many children with autism spectrum disorder as possible, said Hopebridge Vice President of Business Development Chris Sutton.
  • Hopebridge is currently scheduling diagnostic assessments for autism spectrum disorder (ASD) and applied behavior analysis (ABA) therapy evaluations for University Hills.
  • The expansion into Colorado is expected to create more than 650 jobs in the state , which ensures every child at Hopebridge receives one-on-one therapy.
  • The first centers serving the Colorado autism communities are located at:

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol

Retrieved on: 
Tuesday, February 25, 2020
Psychiatry, Organ systems, Psychiatric diagnosis, Medicine, Autism, Pervasive developmental disorders, Developmental neuroscience, Autism therapies, Cannabidiol, CBD

10,568,848, titled Treatment of Autism with Cannabidiol which includes claims directed to methods of treating autism spectrum disorder (ASD) by transdermally administering, via a gel or cream, a therapeutically effective amount of purified cannabidiol (CBD).

Key Points: 
  • 10,568,848, titled Treatment of Autism with Cannabidiol which includes claims directed to methods of treating autism spectrum disorder (ASD) by transdermally administering, via a gel or cream, a therapeutically effective amount of purified cannabidiol (CBD).
  • This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Company's transdermal cannabidiol product candidate, Zygel CBD gel.
  • 10,314,792, titled Treatment of Autism with Cannabidiol which includes claims directed to methods of treating ASD by transdermally administering, via gel or cream, a therapeutically effective amount of synthetic cannabidiol.
  • The efficacy assessments include the Aberrant Behavior Checklist, Parent Rated Anxiety Scale Autism Spectrum Disorder, Autism Impact Measure, and Clinical Global Impression Severity and Improvement.

Axial Biotherapeutics to Present at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders’ Emerging Management Therapies for Childhood Neurodevelopmental Disorders Scientific Symposium

Retrieved on: 
Wednesday, February 5, 2020
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, Neurological disorders, Organ systems, Nervous system, Psychiatry, Developmental neuroscience, Neurodevelopmental disorder, Autism

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Stewart Campbell, Ph.D., Senior Vice President, Research & Development, will present a translational overview of Axials Autism program at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders (CCTRND) Emerging Management Therapies for Childhood Neurodevelopment Disorders Inaugural Scientific Symposium on Thursday, February 6, 2020 at 11:00 AM AEST (Wednesday, February 5, 2020, 7:00 PM ET) at the Queensland Childrens Hospital in South Brisbane, Queensland, Australia.

Key Points: 
  • Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Stewart Campbell, Ph.D., Senior Vice President, Research & Development, will present a translational overview of Axials Autism program at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders (CCTRND) Emerging Management Therapies for Childhood Neurodevelopment Disorders Inaugural Scientific Symposium on Thursday, February 6, 2020 at 11:00 AM AEST (Wednesday, February 5, 2020, 7:00 PM ET) at the Queensland Childrens Hospital in South Brisbane, Queensland, Australia.
  • Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases.
  • The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinsons Disease and Autism Spectrum Disorder.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005198/en/

Global Pipeline Review for High Affinity Nerve Growth Factor Receptor - H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 3, 2020
Health, Pharmaceutical, Branches of biology, Tyrosine kinase receptors, Cell signaling, Transmembrane proteins, Developmental neuroscience, Single-pass transmembrane proteins, Peptide hormones, Tropomyosin receptor kinase A, Neurotrophic factors, Tropomyosin receptor kinase C, Book:Trk Receptor System, Receptor tyrosine kinase

The "High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This latest report outlays comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • It also reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.
  • Drug
    Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies